People in the News

Oct 18, 2018

Mary Padbury, Katherine Bach Kalin

Clinical Genomics announced the appointments of Mary Padbury and Katherine Bach Kalin to its board. Padbury who will be the chairman of the board, has done intellectual property work for Australian and multinational companies. She was most recently a partner and vice chairman of law firm Ashurst. She currently is chairman of the board for Trans-Tasman IP Attorneys.

Kalin has more than 25 years of experience as a senior executive in the healthcare and professional services industries. Most recently, she led corporate strategy at Celgene. Prior to that, she held leadership roles in marketing, sales, strategy, and new bbusiness development at Johnson & Johnson.

Oct 17, 2018

Daniel Kolk

Daniel Kolk has joined XCR Diagnostics as vice president of clinical development. He previously served as senior director of product development for Hologic, where he led development and US Food and Drug Administration clearance of respiratory assays on Hologic's Panther Fusion system. Prior to this he helped develop human papillomavirus and blood screening products at Gen-Probe, which was acquired by Hologic.

Oct 16, 2018

Tom Copa

Asuragen has hired Tom Copa as its SVP, commercial operations. Copa will lead the global sales, marketing, and customer solutions teams for the firm's diagnostics products business. Prior to Asuragen, Copa served as VP of licensed technologies at Luminex, as well as spending over 16 years as a senior executive in several roles at the firm. 

Oct 15, 2018

Robert Ford

Abbott announced that Robert Ford has been named president and chief operating officer. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business.

In addition to his current responsibilities for Medical Devices, Ford will assume responsibility for all of Abbott's operating businesses. He will continue to report to the firm's Chairman and CEO Miles White.

Ford has held various management positions across several of Abbott's businesses, including Diagnostics, Nutrition, and Medical Devices. As head of the firm's Medical Devices business for the past three years, he oversaw the integration of the St. Jude Medical acquisition. He previously led Abbott's Diabetes Care business and the launch of its glucose monitoring system, FreeStyle Libre. 

Oct 12, 2018

David Stark

Parallax Diagnostics has appointed David Stark its president, the company's parent firm Parallax Health Sciences, said. Stark has more than 20 years of experience in healthcare R&D, clinical research, regulatory affairs, and marketing. He was director of development for clinical research organization Spaulding Clinical Research and director of business development, West Coast for MedSource. Before that, he was development director, West Coast for Veristat. 

Oct 12, 2018

Jane Schwebke

Talis Biomedical has appointed Jane Schwebke to its scientific advisory board. Both a professor of medicine in the infectious disease division at the University of Alabama at Birmingham and a consultant to the Jefferson County Department of Health STD clinic, Schwebke previously served as medical director of the Harborview STD Clinic in Seattle and as director for Chicago's STD/HIV Program.

Oct 11, 2018

Jörg Debatin

Jörg Debatin has been appointed chairman of the supervisory board of Hummingbird Diagnostics. Debatin previously served as VP and chief technology officer of GE Healthcare and CEO of Amedes. In addition, he has also served as the medical director and CEO of the University Hospital Hamburg-Eppendorf.

Oct 11, 2018

John Glasspool

VisionGate has appointed John Glasspool as Chief Operating and Strategy Officer and to the firm's board of directors. Glasspool is currently a member of the board of directors of Dalcor. In addition, he is an advisor to MIT Newdigs and leads the FoCUS project, looking at pricing and policy for durable oncology therapies. Glasspool's career includes executive and management responsibilities at pharmaceutical companies, including Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. Glasspool has also served on the board of directors and as president of Vaccines Europe at the Biotechnology Industry Organization.

Oct 10, 2018

Richard Yost

Owlstone Medical appointed Richard Yost to its scientific advisory board. He is a professor and head of analytical chemistry at the University of Florida and has particular expertise in tandem mass spectrometry. Yost is the co-inventor of the triple quadrupole mass spectrometer, Owlstone added. 

Oct 09, 2018

Michel Finance

Michel Finance is leaving his post as CEO of Theradiag, the company announced. No reason was given for his departure. Finance will stay on at Theradiag until Dec. 31. A search for his successor has begun. 

Oct 09, 2018

Susan Evans, Donna Edmonds

ImmunArray announced Susan Evans will become its new CEO, replacing Donna Edmonds, who will become the chair and CEO of ImmunArray's new spinoff called BrainBox Solutions based in Richmond, Virginia.

Evans began her career at Baxter Diagnostics and Dade Behring, where held various positions in R&D including senior vice president. She also held senior R&D postions in Caliper Life Sciences and Life Scan, and was vice president scientific affairs, and vice president/general manager of Beckman Coulter Genomics. 

Edmonds, meanwhile, will remain executive chair of ImmunArray. 

Oct 08, 2018

Stan Lapidus, Howard Heller, Margaret Higham

Atlas Genetics has changed its name to Binx Health and announced several additions to the company, including the appointment of Stan Lapidus as chairman of the board. Lapidus is the founder of Exact Sciences and Helicos BioSciences.

Also, Howard Heller was appointed Binx's chief medical officer while Margaret Higham was named its director of medical affairs. Heller directs infection control and prevention at the Massachusetts Institute of Technology and provides clinical care at Massachusetts General Hospital. Higham is an infectious disease expert and medical director of the Student Health Service at Tufts University.

Oct 04, 2018

David Grenache

The American Association of Clinical Chemistry announced that David Grenache has been elected to serve on the AACC board of directors as president-elect starting in January 2019. He will then serve as the association's president from August 2020 to July 2021, and past president from August 2021 to July 2022. Grenache is the chief scientific officer and medical director of the chemistry, immunology, and esoteric analytic chemistry labs at TriCore Reference Laboratories, and clinical professor of pathology at the University of New Mexico.

Oct 03, 2018

Tom Polen

Tom Polen, who currently serves as president of BD, has been promoted. He will now also serve as BD's Chief Operating Officer. Polen will be responsible for overseeing the firm's three operating segments, its new product development pipeline, and global operations including all manufacturing facilities and supply chain operations. The company has not had a COO since 2016, according to a statement.

Oct 03, 2018

Jürgen Schulze, Alain Baverel

Sysmex Europe announced that Jürgen Schulze, its chairman, long-time president, and CEO, retired at the end of September. He will continue to support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board, the firm said.

Schulze passed the baton to Alain Baverel, who has been transitioning into his role as president and CEO of Sysmex EMEA since April 2018. His role became official Oct. 1.

Baverel joined Sysmex in 2007 as managing director of the newly established affiliate Sysmex France.

Oct 03, 2018

Hayden Jeffreys

Hayden Jeffreys has become group commercial director at Premaitha Health. He joined the company from Cambridge Epigenetix, where he was chief operating officer. Before that, he was interim CEO at ERBA Diagnostics. Jeffreys holds an MSc in management studies from the University of Oxford and a BSc in genetics from Cardiff University.

Oct 02, 2018

Lawrence Culp

Former Danaher President and CEO Lawrence Culp was named the Chairman and CEO of GE on Oct. 1, effective immediately. He replaces John Flannery in the two positions. Culp has been a member of GE's board since April and led Danaher between 2000 and 2014. 

Sep 27, 2018

Joan Martin

Accelerate Diagnostics has announced that Joan Martin has resigned from his position as executive vice president and head of Europe, the Middle East, and Africa, and will be leaving the company for personal reasons. Lawrence Mehren, Accelerate's president and CEO, will oversee operations of the region on an interim basis until the vacancy is filled.

Sep 27, 2018

Laurie Goodman

ClearLight Diagnostics has appointed Laurie Goodman as CEO. Goodman had been serving as interim CEO since 2018 and chief scientific officer since 2015. She will continue serving as board manager and provide executive leadership for the firm moving forward. Prior to ClearLight, Goodman was senior director of scientific and medical affairs for Biodesix, and held senior level positions at Affymetrix, Monogram Biosciences, and Lynx Therapeutics.

Sep 25, 2018

Feng Deng

Feng Deng has joined the board of flow cytometry firm Cytek Biosciences. Deng is the founder of Northern Lights Ventures, which co-led Cytek's Series C financing round, whose completion was announced this week. Prior to Northern Lights, he cofounded NetScreen Technologies, which was later acquired by Juniper Networks for $4.2 billion.

Sep 24, 2018

John Kraeutler, David Phillips, Felicia Williams

John (Jack) Kraeutler has retired from his position as Meridian Bioscience's executive chairman of the board, effective Sept. 30, 2018. Kraeutler retired as CEO of the firm last year after 25 years in that position. Meridian has appointed David Phillips as the new chairman of the board, and has also elected Felicia Williams to the board of directors and to serve on the firm's audit committee, effective September 20, 2018. Williams previously served in financial positions at Macy's and Coca-Cola.

Sep 20, 2018

Hayden Jeffreys

Hayden Jeffreys has taken on a senior commercial role at Premaitha Health and will be appointed to the company's board in the near future. Most recently, he was the COO of Cambridge Epigenetix, and prior to that, interim CEO of ERBA Diagnostics.

Sep 18, 2018

Sam Tsimikas, Michael Davidson, and others

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific, appointed five members to its scientific advisory board. They are Sam Tsimikas; Michael Davidson; Peter Reaven; Dennis Goodman; and H. Robert Superko. Tsimikas is a cardiologist at the University of California, San Diego specializing in lipoprotein. Davidson is a cardiologist at the University of Chicago with a specialty in omega-3 fatty acid metabolism and clinical use, while Reaven is at the University of Arizona where he researches insulin resistance and diabetes. Goodman specializes in integrative medicine at New York University, and Superko is a founder of Berkeley Heart Lab and a specialist in lipoprotein subfractionization.

Sep 14, 2018

Andy Richards

Owlstone Medical appointed Andy Richards to its board as a non-executive director. Richards, an entrepreneur and business angel, has an established track record in founding and scaling up innovative biotech and health technology companies in the UK, the firm said. His early career spans positions with Imperial Chemical Industries and PA Technology, and he was a founder and executive director of Chiroscience until its merger with Celltech in 1999. Since then, he founded, invested in, and helped to scale more than 25 innovative ventures including Vectura, Arakis, and Cambridge Biotechnology.

Sep 12, 2018

Bob Petrou

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry.